Back to Journals » ImmunoTargets and Therapy » Volume 2

Cancer testis antigen and immunotherapy

Authors Krishnadas DK, Bai F, Lucas KG

Received 31 December 2012

Accepted for publication 22 February 2013

Published 18 April 2013 Volume 2013:2 Pages 11—19

DOI https://doi.org/10.2147/ITT.S35570

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Deepa Kolaseri Krishnadas, Fanqi Bai, Kenneth G Lucas

Department of Pediatrics, Division of Hematology/Oncology, University of Louisville, KY, USA

Abstract: The identification of cancer testis (CT) antigens has been an important advance in determining potential targets for cancer immunotherapy. Multiple previous studies have shown that CT antigen vaccines, using both peptides and dendritic cell vaccines, can elicit clinical and immunologic responses in several different tumors. This review details the expression of melanoma antigen family A, 1 (MAGE-A1), melanoma antigen family A, 3 (MAGE-A3), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) in various malignancies, and presents our current understanding of CT antigen based immunotherapy.

Keywords: cancer testis antigens, immunotherapy, vaccine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]